Selected research
Industry Research
Etiracetam Industry Research Report 2026
Market perspective
The global Etiracetam market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Etiracetam is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Etiracetam is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Etiracetam is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Etiracetam include UCB, APOTEX, Aurobindo, Hikma, Lupin, Pharmascience, Shenzhen Salubris Pharmaceuticals, Viatris and Changzhou Pharmaceutical Factory, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Etiracetam market in terms of revenue (US$ million) and, where applicable, sales volume (kg), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/kg) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Etiracetam Market by Company
UCB
APOTEX
Aurobindo
Hikma
Lupin
Pharmascience
Shenzhen Salubris Pharmaceuticals
Viatris
Changzhou Pharmaceutical Factory
Chengdu Leer Pharmaceutical
Zhejiang Huahai Pharmaceutical
China Resources Saike Pharmaceutical
Zhejiang Jingxin Pharmaceutical
Hainan Poly Pharm
Jiangsu Wangao Pharmaceutical
Etiracetam Segment by Type
Levetiracetam
Devetiracetam
Etiracetam Segment by Application
Hospital
Clinic
Etiracetam Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Etiracetam market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Etiracetam and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Etiracetam.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Etiracetam manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Etiracetam by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Etiracetam in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Levetiracetam
- Devetiracetam
Applications
- Hospital
- Clinic
Companies covered
- UCB
- APOTEX
- Aurobindo
- Hikma
- Lupin
- Pharmascience
- Shenzhen Salubris Pharmaceuticals
- Viatris
- Changzhou Pharmaceutical Factory
- Chengdu Leer Pharmaceutical
- Zhejiang Huahai Pharmaceutical
- China Resources Saike Pharmaceutical
- Zhejiang Jingxin Pharmaceutical
- Hainan Poly Pharm
- Jiangsu Wangao Pharmaceutical
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Etiracetam Market Size (2021-2032)
- 2.2.2 Global Etiracetam Sales (2021-2032)
- 2.2.3 Global Etiracetam Market Average Price (2021-2032)
- 2.3 Etiracetam by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Levetiracetam
- 2.3.3 Devetiracetam
- 2.4 Etiracetam by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Etiracetam Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Etiracetam Sales (kg) of Manufacturers (2021-2026)
- 3.3 Global Etiracetam Revenue of Manufacturers (2021-2026)
- 3.4 Global Etiracetam Average Price by Manufacturers (2021-2026)
- 3.5 Global Etiracetam Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Etiracetam, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Etiracetam, Product Type & Application
- 3.8 Global Manufacturers of Etiracetam, Established Date
- 3.9 Global Etiracetam Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 UCB
- 4.1.1 UCB Company Information
- 4.1.2 UCB Business Overview
- 4.1.3 UCB Etiracetam Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 UCB Etiracetam Product Portfolio
- 4.1.5 UCB Recent Developments
- 4.2 APOTEX
- 4.2.1 APOTEX Company Information
- 4.2.2 APOTEX Business Overview
- 4.2.3 APOTEX Etiracetam Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 APOTEX Etiracetam Product Portfolio
- 4.2.5 APOTEX Recent Developments
- 4.3 Aurobindo
- 4.3.1 Aurobindo Company Information
- 4.3.2 Aurobindo Business Overview
- 4.3.3 Aurobindo Etiracetam Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Aurobindo Etiracetam Product Portfolio
- 4.3.5 Aurobindo Recent Developments
- 4.4 Hikma
- 4.4.1 Hikma Company Information
- 4.4.2 Hikma Business Overview
- 4.4.3 Hikma Etiracetam Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Hikma Etiracetam Product Portfolio
- 4.4.5 Hikma Recent Developments
- 4.5 Lupin
- 4.5.1 Lupin Company Information
- 4.5.2 Lupin Business Overview
- 4.5.3 Lupin Etiracetam Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Lupin Etiracetam Product Portfolio
- 4.5.5 Lupin Recent Developments
- 4.6 Pharmascience
- 4.6.1 Pharmascience Company Information
- 4.6.2 Pharmascience Business Overview
- 4.6.3 Pharmascience Etiracetam Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Pharmascience Etiracetam Product Portfolio
- 4.6.5 Pharmascience Recent Developments
- 4.7 Shenzhen Salubris Pharmaceuticals
- 4.7.1 Shenzhen Salubris Pharmaceuticals Company Information
- 4.7.2 Shenzhen Salubris Pharmaceuticals Business Overview
- 4.7.3 Shenzhen Salubris Pharmaceuticals Etiracetam Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Shenzhen Salubris Pharmaceuticals Etiracetam Product Portfolio
- 4.7.5 Shenzhen Salubris Pharmaceuticals Recent Developments
- 4.8 Viatris
- 4.8.1 Viatris Company Information
- 4.8.2 Viatris Business Overview
- 4.8.3 Viatris Etiracetam Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Viatris Etiracetam Product Portfolio
- 4.8.5 Viatris Recent Developments
- 4.9 Changzhou Pharmaceutical Factory
- 4.9.1 Changzhou Pharmaceutical Factory Company Information
- 4.9.2 Changzhou Pharmaceutical Factory Business Overview
- 4.9.3 Changzhou Pharmaceutical Factory Etiracetam Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Changzhou Pharmaceutical Factory Etiracetam Product Portfolio
- 4.9.5 Changzhou Pharmaceutical Factory Recent Developments
- 4.10 Chengdu Leer Pharmaceutical
- 4.10.1 Chengdu Leer Pharmaceutical Company Information
- 4.10.2 Chengdu Leer Pharmaceutical Business Overview
- 4.10.3 Chengdu Leer Pharmaceutical Etiracetam Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Chengdu Leer Pharmaceutical Etiracetam Product Portfolio
- 4.10.5 Chengdu Leer Pharmaceutical Recent Developments
- 4.11 Zhejiang Huahai Pharmaceutical
- 4.11.1 Zhejiang Huahai Pharmaceutical Company Information
- 4.11.2 Zhejiang Huahai Pharmaceutical Business Overview
- 4.11.3 Zhejiang Huahai Pharmaceutical Etiracetam Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Zhejiang Huahai Pharmaceutical Etiracetam Product Portfolio
- 4.11.5 Zhejiang Huahai Pharmaceutical Recent Developments
- 4.12 China Resources Saike Pharmaceutical
- 4.12.1 China Resources Saike Pharmaceutical Company Information
- 4.12.2 China Resources Saike Pharmaceutical Business Overview
- 4.12.3 China Resources Saike Pharmaceutical Etiracetam Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 China Resources Saike Pharmaceutical Etiracetam Product Portfolio
- 4.12.5 China Resources Saike Pharmaceutical Recent Developments
- 4.13 Zhejiang Jingxin Pharmaceutical
- 4.13.1 Zhejiang Jingxin Pharmaceutical Company Information
- 4.13.2 Zhejiang Jingxin Pharmaceutical Business Overview
- 4.13.3 Zhejiang Jingxin Pharmaceutical Etiracetam Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Zhejiang Jingxin Pharmaceutical Etiracetam Product Portfolio
- 4.13.5 Zhejiang Jingxin Pharmaceutical Recent Developments
- 4.14 Hainan Poly Pharm
- 4.14.1 Hainan Poly Pharm Company Information
- 4.14.2 Hainan Poly Pharm Business Overview
- 4.14.3 Hainan Poly Pharm Etiracetam Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Hainan Poly Pharm Etiracetam Product Portfolio
- 4.14.5 Hainan Poly Pharm Recent Developments
- 4.15 Jiangsu Wangao Pharmaceutical
- 4.15.1 Jiangsu Wangao Pharmaceutical Company Information
- 4.15.2 Jiangsu Wangao Pharmaceutical Business Overview
- 4.15.3 Jiangsu Wangao Pharmaceutical Etiracetam Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Jiangsu Wangao Pharmaceutical Etiracetam Product Portfolio
- 4.15.5 Jiangsu Wangao Pharmaceutical Recent Developments
5 Global Etiracetam Market Scenario by Region
- 5.1 Global Etiracetam Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Etiracetam Sales by Region: 2021-2032
- 5.2.1 Global Etiracetam Sales by Region: 2021-2026
- 5.2.2 Global Etiracetam Sales by Region: 2027-2032
- 5.3 Global Etiracetam Revenue by Region: 2021-2032
- 5.3.1 Global Etiracetam Revenue by Region: 2021-2026
- 5.3.2 Global Etiracetam Revenue by Region: 2027-2032
- 5.4 North America Etiracetam Market Facts & Figures by Country
- 5.4.1 North America Etiracetam Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Etiracetam Sales by Country (2021-2032)
- 5.4.3 North America Etiracetam Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Etiracetam Market Facts & Figures by Country
- 5.5.1 Europe Etiracetam Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Etiracetam Sales by Country (2021-2032)
- 5.5.3 Europe Etiracetam Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Etiracetam Market Facts & Figures by Country
- 5.6.1 Asia Pacific Etiracetam Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Etiracetam Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Etiracetam Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Etiracetam Market Facts & Figures by Country
- 5.7.1 South America Etiracetam Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Etiracetam Sales by Country (2021-2032)
- 5.7.3 South America Etiracetam Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Etiracetam Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Etiracetam Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Etiracetam Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Etiracetam Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Etiracetam Sales by Type (2021-2032)
- 6.1.1 Global Etiracetam Sales by Type (2021-2032) & (kg)
- 6.1.2 Global Etiracetam Sales Market Share by Type (2021-2032)
- 6.2 Global Etiracetam Revenue by Type (2021-2032)
- 6.2.1 Global Etiracetam Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Etiracetam Revenue Market Share by Type (2021-2032)
- 6.3 Global Etiracetam Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Etiracetam Sales by Application (2021-2032)
- 7.1.1 Global Etiracetam Sales by Application (2021-2032) & (kg)
- 7.1.2 Global Etiracetam Sales Market Share by Application (2021-2032)
- 7.2 Global Etiracetam Revenue by Application (2021-2032)
- 7.2.1 Global Etiracetam Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Etiracetam Revenue Market Share by Application (2021-2032)
- 7.3 Global Etiracetam Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Etiracetam Value Chain Analysis
- 8.1.1 Etiracetam Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Etiracetam Production Mode & Process
- 8.2 Etiracetam Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Etiracetam Distributors
- 8.2.3 Etiracetam Customers
9 Global Etiracetam Analyzing Market Dynamics
- 9.1 Etiracetam Industry Trends
- 9.2 Etiracetam Industry Drivers
- 9.3 Etiracetam Industry Opportunities and Challenges
- 9.4 Etiracetam Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst